Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038762 | 1.00 | SLC6A2 (0.58) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL10253191 | 1.00 | SLC6A2 (0.58) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL31545954 | 0.85 | SLC6A2 (0.52) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL1619118 | 0.84 | SLC6A2 (0.56) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL1153493 | 0.83 | KDM4E (0.61) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7066881 | 0.83 | SLC6A2 (0.54) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL8540631 | 0.83 | KDM4E (0.61) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| SCHEMBL1153491 | 0.83 | KDM4E (0.61) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4524323 | 0.81 | KDM4E (0.59) | SLC6A2TAAR1MAOASLC6A4SLC6A3 | |
| Water SCHEMBL11513174 | 0.81 | KDM4E (0.59) | SLC6A2TAAR1MAOASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210040069-A1 | DACOS Type NNRTIS Amino Acid Ester Derivative, Preparation Method Thereof, Pharmaceutical Composition, and Application Thereof | YUNNAN UNIVERSITY (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | NORAMCO, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-7183275-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-0344425-B1 | N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents | WARNER LAMBERT CO (US) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | SLC6A2 2130/4885TAAR1 4691/4885MAOA 3791/4885 |
| US-20210040069-A1 | DACOS Type NNRTIS Amino Acid Ester Derivative, Preparation Method Thereof, Pharmaceutical Composition, and Application Thereof | DAO, ASNS, DDO | SLC6A2 1467/4885TAAR1 3228/4885MAOA 551/4885 |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | COMT, MGAM, GAA | SLC6A2 14/4885TAAR1 297/4885MAOA 56/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | SLC6A2 1302/4885TAAR1 173/4885MAOA 3040/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | SLC6A2 3311/4885TAAR1 4725/4885MAOA 2103/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | SLC6A2 3311/4885TAAR1 4725/4885MAOA 2103/4885 |
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | NLN, GAP43, PSEN2 | SLC6A2 959/4885TAAR1 3429/4885MAOA 2063/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | SLC6A2 2130/4885TAAR1 4691/4885MAOA 3791/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | SLC6A2 1606/4885TAAR1 99/4885MAOA 2919/4885 |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | GAP43, NLN, SNAP29 | SLC6A2 505/4885TAAR1 3292/4885MAOA 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.